• Revenue up 46% to $66.1 million
• Loss of $8.2 million, down 1,068% from prior year
• Strong growth driven by deployment of PhotonAssay™ Max Units

Chrysos Corporation Ltd has released its Appendix 4E Preliminary Final Report for the year ended 30 June 2025. The company reported revenue of $66.1 million, up 46% from the previous corresponding period. However, the company recorded a loss of $8.2 million, down 1,068% from the prior year. The growth in revenue was driven by the continued deployment of the company's PhotonAssay™ technology, with PhotonAssay™ revenue increasing by 49% to $66 million. The company also saw growth in its international markets, with revenue from the APAC, EMEA, and Americas regions all increasing compared to the prior year.Expenses for the year increased, with PhotonAssay™ expenses up 55%, employee benefit expenses up 51%, and depreciation and amortisation expense up 33%. This resulted in the significant decline in profitability compared to the prior year.The company ended the year with a strong balance sheet, with $21.5 million in cash and cash equivalents. It also had $186.1 million in property, plant, and equipment, reflecting the ongoing investment in the deployment of its PhotonAssay™ technology.Overall, the FY2025 results demonstrate the continued growth of Chrysos Corporation's business, driven by the successful rollout of its PhotonAssay™ technology. However, the company's profitability was impacted by the increased costs associated with this growth.

The company's revenue and EBITDA are within the previously provided guidance range.